ScreenerHero

BHCBausch Health Companies Inc.

NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · bauschhealth.com
6.440USDMkt Cap: 2.41B $P/E: —

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The comp…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap2.41B $
Enterprise Value22.33B $
Revenue (TTM)10.85B $
Gross Profit7.25B $
Net Income (TTM)157.00M $
Revenue/Share29.12 USD
Last Price6.440 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20.3K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA0717341071
Valuation
P/E (Trailing)—
P/E (Forward)1.54
PEG0.01
EV/EBITDA5.71
EV/Revenue2.06
P/S0.22
P/B-1.36
EPS (TTM)-2.94
EPS (Forward)4.19
52W Range
6.37513% of range6.870
52W High6.870 USD
52W Low6.375 USD
Profitability
Gross Margin70.65%
Oper. Margin27.17%
EBITDA Margin36.01%
Profit Margin1.53%
ROE-28.34%
ROA0.60%
Growth
Revenue Growth12.70%
Earnings Growth70.40%
Cash Flow & Leverage
Operating CF1.40B $
CapEx (TTM)407.00M $
FCF Margin13.21%
FCF Yield59.52%
Net Debt18.95B $
Net Debt/EBITDA4.85
Balance Sheet
Debt/Equity-37.64
Current Ratio1.44
Quick Ratio0.90
Book Value/Sh-4.7370 USD
Cash/Share4.880 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield6.52%
Payout Ratio0.00%
Ex-Div DateNov 10, 2010
Pay Date—
Splits
Last Split2:1
Split DateOct 16, 2000
Analyst Consensus
Rating—
Target (Mean)7.500 USD
Upside (mean)+16.5%
Target Range6.500 USD – 9.000 USD
$6.500+16.5% to mean$9.000
# Analysts5
Ownership
Shares Out.373.99M
Float260.57M
Insiders11.12%
Institutions65.06%
Short Interest
Short Ratio2.1d
Short % Float2.53%
Short % Out.2.02%
Shares Short7.56M
Short (prev mo.)7.33M
Technical
SMA 505.372 (+19.9%)
SMA 2005.857 (+9.9%)
Beta0.38
S&P 52W Chg19.18%
Avg Vol (30d)3.73M
Avg Vol (10d)2.63M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—